 | |
| Clinical data | |
|---|---|
| Trade names | CalBlock,AZUSA,Azovas |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.162.151 |
| Chemical and physical data | |
| Formula | C33H34N4O6 |
| Molar mass | 582.657 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Azelnidipine (INN; marketed under the brand nameCalBlock — カルブロック) is adihydropyridinecalcium channel blocker. Azelnidipine is L and T calcium channel blocker. It is sold inJapan byDaiichi-Sankyo pharmaceuticals, Inc.Unlikenicardipine, it has a gradual onset and has a long-lasting antihypertensive effect, with little increase in heart rate. Drug Controller General Of India (DCGI) has approved the use of azelnipine in India. It is launched under the brand name Azusa (ajanta pharma ltd.)[1] In 2020.
 | Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byexpanding it. |